Valuation: Quanterix Corporation

Market Cap 141M 121M 113M 104M 195M 13.53B 197M 1.34B 522M 6.8B 531M 519M 22.48B P/E 2026 *
-1.53x
P/E 2027 * -2.41x
Enterprise Value 141M 121M 113M 104M 195M 13.53B 197M 1.34B 522M 6.8B 531M 519M 22.48B EV / Sales 2026 *
0.98x
EV / Sales 2027 * 0.89x
Free-Float
93.69%
Yield 2026 *
-
Yield 2027 * -
1 day-4.17%
1 week+15.44%
Current month-14.08%
1 month-24.69%
3 months+13.26%
6 months-48.09%
Current year-52.99%
1 week 2.65
Extreme 2.65
3.25
1 month 2.15
Extreme 2.15
4.04
Current year 2.15
Extreme 2.15
8.77
1 year 2.15
Extreme 2.15
8.77
3 years 2.15
Extreme 2.15
29.7
5 years 2.15
Extreme 2.15
60.92
10 years 2.15
Extreme 2.15
92.57
Manager TitleAgeSince
Chief Executive Officer 59 2026-01-18
Director of Finance/CFO 50 2026-06-21
Chief Operating Officer - 2026-05-13
Director TitleAgeSince
Director/Board Member 63 2022-06-05
Chairman 64 2025-03-23
Director/Board Member 48 2024-08-18
Date Insider Type Main position Quantity % Market Cap.
8/17/26 Fiscal year

Chairman

5,604 0.0121%
8/15/26 Fiscal year

Chief Technology Officer

3,583 0.0077%
8/13/26 Buy

Chairman

72,245 0.1555%
Change 5-day change 1-year change 3-year change Capi.($)
-4.17%+15.44%-38.22%-87.71% 148M
+0.27%+6.97%+30.08%+18.23% 232B
+1.36%+8.10%+7.33%-12.52% 152B
+1.16%-3.98%-19.38%+32.14% 132B
+2.03%-2.82%-52.12%-0.10% 71.55B
-0.04%-1.98%+10.63%+17.63% 51.78B
+0.98%+2.26%-15.88%-11.61% 51.75B
+1.73%+7.05%+35.72%+33.77% 44.14B
+1.49%-0.36%+41.41%+53.72% 39.76B
+1.03%+1.53%+2.28%+8.48% 33.45B
Average +0.62%+3.12%+0.18%+5.20% 80.87B
Weighted average by Cap. +1.01%+3.01%+5.96%+13.33%

Financials

2026 *2027 *
Net sales 144M 123M 115M 106M 198M 13.76B 201M 1.36B 531M 6.91B 540M 528M 22.86B 158M 135M 127M 116M 218M 15.12B 221M 1.5B 584M 7.6B 594M 581M 25.13B
Net income -92.79M -79.48M -74.37M -68.08M -128M -8.88B -129M -879M -343M -4.46B -348M -341M -14.75B -70.09M -60.04M -56.17M -51.42M -96.5M -6.71B -97.78M -664M -259M -3.37B -263M -257M -11.14B
Net Debt - -
Logo Quanterix Corporation
Quanterix Corporation is a life sciences company. The Company is focused on ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development proprietary digital Simoa detection technology enables customers to reliably detect protein biomarkers at ultra-low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. Its Simoa bead-based digital immunoassays utilize the basic principles of conventional bead-based sandwich ELISA. The HD-X is the Company's flagship instrument that empowers biomarker research and accelerates drug development. Its SR-X instrument is a compact benchtop instrument with a lower price point, more flexible assay preparation, and a wider range of applications. The Company's Spatial Biology solutions measure protein expression and cellular phenotypes within intact tissue while preserving spatial context and tissue architecture.
Employees
450
Date Price Change Volume
26-08-21 US$2.990 -4.17% 320,547
26-08-20 US$3.120 +5.41% 579,073
26-08-19 US$2.960 +10.45% 847,242
26-08-18 US$2.680 -8.22% 796,275
26-08-17 US$2.920 +12.74% 1,342,490
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
2.990USD
Average target price
3.000USD
Spread / Average Target
+0.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. QTRX Stock